1
|
Alban TJ, Grabowski MM, Otvos B, Bayik D, Wang W, Zalavadia A, Makarov V, Troike K, McGraw M, Rabljenovic A, Lauko A, Neumann C, Roversi G, Waite KA, Cioffi G, Patil N, Tran TT, McCortney K, Steffens A, Diaz CM, Brown JM, Egan KM, Horbinski CM, Barnholtz-Sloan JS, Rajappa P, Vogelbaum MA, Bucala R, Chan TA, Ahluwalia MS, Lathia JD. The MIF promoter SNP rs755622 is associated with immune activation in glioblastoma. JCI Insight 2023; 8:e160024. [PMID: 37252795 PMCID: PMC10371339 DOI: 10.1172/jci.insight.160024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Accepted: 05/25/2023] [Indexed: 06/01/2023] Open
Abstract
Intratumoral heterogeneity is a defining hallmark of glioblastoma, driving drug resistance and ultimately recurrence. Many somatic drivers of microenvironmental change have been shown to affect this heterogeneity and, ultimately, the treatment response. However, little is known about how germline mutations affect the tumoral microenvironment. Here, we find that the single-nucleotide polymorphism (SNP) rs755622 in the promoter of the cytokine macrophage migration inhibitory factor (MIF) is associated with increased leukocyte infiltration in glioblastoma. Furthermore, we identified an association between rs755622 and lactotransferrin expression, which could also be used as a biomarker for immune-infiltrated tumors. These findings demonstrate that a germline SNP in the promoter region of MIF may affect the immune microenvironment and further reveal a link between lactotransferrin and immune activation.
Collapse
Affiliation(s)
- Tyler J. Alban
- Department of Cardiovascular & Metabolic Sciences and Imaging Core, Lerner Research Institute
- Center for Immunotherapy and Precision Oncology, and
| | - Matthew M. Grabowski
- Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio, USA
| | - Balint Otvos
- Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio, USA
| | - Defne Bayik
- Department of Cardiovascular & Metabolic Sciences and Imaging Core, Lerner Research Institute
| | - Wesley Wang
- Nationwide Children’s Hospital, Institute for Genomic Medicine, Departments of Pediatrics and Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Ajay Zalavadia
- Department of Cardiovascular & Metabolic Sciences and Imaging Core, Lerner Research Institute
| | - Vlad Makarov
- Center for Immunotherapy and Precision Oncology, and
| | - Katie Troike
- Department of Cardiovascular & Metabolic Sciences and Imaging Core, Lerner Research Institute
| | - Mary McGraw
- Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio, USA
| | - Anja Rabljenovic
- Department of Cardiovascular & Metabolic Sciences and Imaging Core, Lerner Research Institute
| | - Adam Lauko
- Department of Cardiovascular & Metabolic Sciences and Imaging Core, Lerner Research Institute
| | - Chase Neumann
- Department of Cardiovascular & Metabolic Sciences and Imaging Core, Lerner Research Institute
| | - Gustavo Roversi
- Department of Cardiovascular & Metabolic Sciences and Imaging Core, Lerner Research Institute
| | - Kristin A. Waite
- Division of Cancer Epidemiology and Genetics, Trans-Divisional Research Program, Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland, USA
| | - Gino Cioffi
- Division of Cancer Epidemiology and Genetics, Trans-Divisional Research Program, Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland, USA
| | - Nirav Patil
- University Hospitals Research and Education Institute, Cleveland, Ohio, USA
| | - Thuy T. Tran
- Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, USA
| | - Kathleen McCortney
- Departments of Pathology and Neurosurgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
| | - Alicia Steffens
- Departments of Pathology and Neurosurgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
| | | | - J. Mark Brown
- Department of Cardiovascular & Metabolic Sciences and Imaging Core, Lerner Research Institute
- Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, Ohio, USA
- Case Comprehensive Cancer Center, Cleveland, Ohio, USA
| | - Kathleen M. Egan
- Departments of Pathology and Neurosurgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
| | - Craig M. Horbinski
- Departments of Pathology and Neurosurgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
| | - Jill S. Barnholtz-Sloan
- Division of Cancer Epidemiology and Genetics, Trans-Divisional Research Program, Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland, USA
| | - Prajwal Rajappa
- Nationwide Children’s Hospital, Institute for Genomic Medicine, Departments of Pediatrics and Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Michael A. Vogelbaum
- Departments of Cancer Epidemiology and Neuro-Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA
| | - Richard Bucala
- Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, USA
| | - Timothy A. Chan
- Center for Immunotherapy and Precision Oncology, and
- Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio, USA
- Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, Ohio, USA
- Case Comprehensive Cancer Center, Cleveland, Ohio, USA
| | | | - Justin D. Lathia
- Department of Cardiovascular & Metabolic Sciences and Imaging Core, Lerner Research Institute
- Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio, USA
- Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, Ohio, USA
- Case Comprehensive Cancer Center, Cleveland, Ohio, USA
| |
Collapse
|
2
|
Chuo D, Lin D, Yin M, Chen Y. Genetic Variants of the MIF Gene and Susceptibility of Rectal Cancer. Pharmgenomics Pers Med 2021; 14:55-60. [PMID: 33469341 PMCID: PMC7812028 DOI: 10.2147/pgpm.s282653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Accepted: 12/05/2020] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Rectal cancer (RC) has been documented to be a highly invasive malignant neoplasm worldwide. Macrophage migration inhibitory factor (MIF) is a multifunctional cytokine involved in cell-mediated immunity, immunoregulation, inflammation. In vitro and in vivo studies have identified that MIF was involved in the carcinogenesis and progression of RC. PATIENTS AND METHODS This case-control study evaluated associations of genetic variants of the MIF gene and serum level of MIF with susceptibility of RC. RESULTS We found MIF level was associated with an increased risk of RC (OR for per unit: 1.38, 95% CI:1.32-1.44; P < 0.001). Both MIF rs2012133 (OR = 1.30; 95% CIs = 1.08-1.58; P = 0.007) and rs755622 (OR = 1.45; 95% CIs = 1.15-1.82; P = 0.002) were significantly associated with increased risk of RC. Besides, we also found MIF rs5844572 was significantly associated with increased susceptibility of RC, with OR for per CATT repeat of 1.28 (95% CIs: 1.16-1.41; P < 0.001). Further, we found all three variants of the MIF gene, rs5844572, rs2012133 and rs755622, could increase serum level of MIF. CONCLUSION This study suggests that MIF plays an important role in the carcinogenesis of RC and could be used as a biomarker for early detection and prediction of RC.
Collapse
Affiliation(s)
- Dongyu Chuo
- Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning Province110042, People’s Republic of China
| | - Dapeng Lin
- Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning Province110042, People’s Republic of China
| | - Mingdi Yin
- Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning Province110042, People’s Republic of China
| | - Yuze Chen
- Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning Province110042, People’s Republic of China
| |
Collapse
|
3
|
Pehlivan M, Nursal AF, Gündeş İ, Oyacı Y, Kıvanç D, Pehlivan S. Role of MIF-173G/C and Mbl2 Codon 54A/B Variants in the Risk of Multiple Myeloma: An Association Study. Endocr Metab Immune Disord Drug Targets 2020; 21:925-931. [PMID: 32811420 DOI: 10.2174/1871530320999200818102731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Revised: 07/08/2020] [Accepted: 07/20/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Multiple myeloma (MM) is a malignant disease manifested by the clonal proliferation of atypical plasma cells. Macrophage inhibitory factor (MIF) is one of the pleiotropic regulators in various biological and cellular processes. Mannose-binding lectin (MBL) is a crucial protein involved in the lectin pathway of the immune system. OBJECTIVE We aimed to assess whether variants of MIF and MBL2 genes are associated with MM among a Turkish population. METHODS We analyzed the MIF-173G/C (rs755622) and MBL2 codon 54A/B (rs1800450) variants in 200 patients with MM and 200 healthy control subjects using a polymerase chain reaction (PCR) followed by restriction endonuclease digestion. There was also an evaluation of the patients undergoing autologous stem-cell transplantation (ASCT) for these variants. RESULTS AA and BB genotypes of MBL2 codon 54A/B increased in the patients as compared to the controls (p=0.008, p=0.001, respectively). The subjects carrying AA and BB genotypes of MBL2 were at high risk of development of susceptibility to MM by 7.377 and 8.812 times, respectively. The distribution of MBL2 codon 54A/B alleles was similar between the groups (p>0 .05). There was no statistical difference between the patients and controls in the genotype and allele frequencies of the MIF- 173G/C variant (p>0 .05). The patients undergoing ASCT, MBL2 codon 54A/B AA and BB genotypes also showed association with increased risk for MM (p=0.004, p=0.001, respectively). CONCLUSION As far as we know, this is the first report of the study on an association between these variants and MM in our population. Our results indicate that the MBL2 codon 54A/B variant may be associated with susceptibility to MM.
Collapse
Affiliation(s)
- Mustafa Pehlivan
- Department of Hematology, Gaziantep Univesity, Faculty of Medicine, Gaziantep, Turkey
| | - Ayşe F Nursal
- Department of Medical Genetics, Hitit University, Faculty of Medicine, Corum, Turkey
| | - İlknur Gündeş
- Department of Hematology, Gaziantep Univesity, Faculty of Medicine, Gaziantep, Turkey
| | - Yasemin Oyacı
- Department of Medical Biology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
| | - Demet Kıvanç
- Department of Medical Biology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
| | - Sacide Pehlivan
- Department of Medical Biology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
| |
Collapse
|
4
|
Avalos‐Navarro G, Del Toro‐Arreola A, Daneri‐Navarro A, Quintero‐Ramos A, Bautista‐Herrera LA, Franco Topete RA, Anaya Macias BU, Javalera Castro DI, Morán‐Mendoza ADJ, Oceguera‐Villanueva A, Topete‐Camacho A, Muñoz‐Valle JF. Association of the genetic variants (-794 CATT5-8 and -173 G > C) of macrophage migration inhibitory factor (MIF) with higher soluble levels of MIF and TNFα in women with breast cancer. J Clin Lab Anal 2020; 34:e23209. [PMID: 31978276 PMCID: PMC7246356 DOI: 10.1002/jcla.23209] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Revised: 12/11/2019] [Accepted: 12/25/2019] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Functional variants -173 G > C (rs755622) and -794CATT5-8 (rs5844572) MIF gene have been associated with the risk in several types of cancer, as well as with the increase of soluble levels of MIF and TNFα. However, in previous studies contradictory and uncertain results have been presented on the implication of MIF polymorphisms with the association in cancer, specifically in breast cancer (BC). We investigated whether the variants are associated with the susceptibility to develop BC and the soluble levels of MIF and TNFα in women with BC from western Mexico. MATERIALS AND METHODS A total of 152 women with BC and 182 control subjects (CS) were enrolled in this study. The determination of genotypes -173 G > C and -794 CATT5-8 MIF polymorphisms was performed by PCR-RFLP and PCR, respectively. In addition, the soluble levels of MIF and TNFα in both studied groups were quantified by ELISA and MILLIPLEX assay, respectively. RESULTS The most frequent allele found in BC was the G (74.3%) and 6 (54%) in the variants -173G > C and -794 CATT5-8 , respectively, without significant differences in both groups. Nevertheless, the women with BC carriers -173*C and -794CATT7 have higher levels of MIF in comparison with CS. An increase of MIF (BC: 11.1 ng/mL vs CS: 5.2 ng/mL, P < .001) and TNFα (BC: 24.9 ng/mL vs CS: 9.9 pg/mL, P < .001) was found. CONCLUSION The functional variants of MIF are not genetic susceptibility markers for BC. Nevertheless, the alleles -173*C and -794CATT7 are associated with the increase of MIF circulating in women with BC.
Collapse
Affiliation(s)
- Guadalupe Avalos‐Navarro
- Laboratorio de InmunologíaDepartamento de FisiologíaCUCSUniversidad de GuadalajaraGuadalajaraMéxico
| | - Alicia Del Toro‐Arreola
- Laboratorio de InmunologíaDepartamento de FisiologíaCUCSUniversidad de GuadalajaraGuadalajaraMéxico
| | - Adrián Daneri‐Navarro
- Laboratorio de InmunologíaDepartamento de FisiologíaCUCSUniversidad de GuadalajaraGuadalajaraMéxico
| | - Antonio Quintero‐Ramos
- Laboratorio de InmunologíaDepartamento de FisiologíaCUCSUniversidad de GuadalajaraGuadalajaraMéxico
| | - Luis Alberto Bautista‐Herrera
- Departamento de Biología Molecular y GenómicaInstituto de Investigación en Ciencias Biomédicas (IICB)Universidad de GuadalajaraGuadalajaraMéxico
| | - Ramon Antonio Franco Topete
- Laboratorio de PatologíaDepartamento de Patología y MicrobiologíaCUCSUniversidad de GuadalajaraGuadalajaraMéxico
- OPD Hospital Civil de Guadalajara“Nuevo Hospital Civil, Juan I. Menchaca”GuadalajaraMéxico
| | - Brian Uriel Anaya Macias
- Departamento de Biología Molecular y GenómicaInstituto de Investigación en Ciencias Biomédicas (IICB)Universidad de GuadalajaraGuadalajaraMéxico
| | | | | | | | - Antonio Topete‐Camacho
- Laboratorio de InmunologíaDepartamento de FisiologíaCUCSUniversidad de GuadalajaraGuadalajaraMéxico
| | - José Francisco Muñoz‐Valle
- Departamento de Biología Molecular y GenómicaInstituto de Investigación en Ciencias Biomédicas (IICB)Universidad de GuadalajaraGuadalajaraMéxico
| |
Collapse
|
5
|
Illescas O, Gomez-Verjan JC, García-Velázquez L, Govezensky T, Rodriguez-Sosa M. Macrophage Migration Inhibitory Factor -173 G/C Polymorphism: A Global Meta-Analysis across the Disease Spectrum. Front Genet 2018; 9:55. [PMID: 29545822 PMCID: PMC5839154 DOI: 10.3389/fgene.2018.00055] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2017] [Accepted: 02/06/2018] [Indexed: 12/13/2022] Open
Abstract
Human macrophage migration inhibitory factor (MIF) is a cytokine that plays a role in several metabolic and inflammatory processes. Single nucleotide polymorphism (SNP) -173 G/C (rs755622) on MIF gene has been associated with numerous diseases, such as arthritis and cancer. However, most of the reports concerning the association of MIF with these and other pathologies are inconsistent and remain quite controversial. Therefore, we performed a meta-analysis from 96 case-control studies on -173 G/C MIF SNP and stratified the data according to the subjects geographic localization or the disease pathophysiology, in order to determine a more meaningful significance to this SNP. The polymorphism was strongly associated with an increased risk in autoimmune-inflammatory, infectious and age-related diseases on the dominant (OR: 0.74 [0.58-0.93], P < 0.01; OR: 0.81 [0.74-0.89], P < 0.0001; and OR: 0.81 [0.76-0.87], P < 0.0001, respectively) and the recessive models (OR: 0.74 [0.57-0.095], P < 0.01; OR: 0.66 [0.48-0.92], P < 0.0154; and OR: 0.70 [0.60-0.82], P < 0.0001, respectively). Also, significant association was found in the geographic localization setting for Asia, Europe and Latin America subdivisions in the dominant (OR: 0.76 [0.69-0.84], P < 0.0001; OR: 0.77 [0.72-0.83], P < 0.0001; OR: 0.61 [0.44-0.83], P-value: 0.0017, respectively) and overdominant models (OR: 0.85 [0.77-0.94], P < 0.0001; OR: 0.80 [0.75-0.86], P < 0.0001; OR: 0.73 [0.63-0.85], P-value: 0.0017, respectively). Afterwards, we implemented a network meta-analysis to compare the association of the polymorphism for two different subdivisions. We found a stronger association for autoimmune than for age-related or autoimmune-inflammatory diseases, and stronger association for infectious than for autoimmune-inflammatory diseases. We report for the first time a meta-analysis of rs755622 polymorphism with a variety of stratified diseases and populations. The study reveals a strong association of the polymorphism with autoimmune and infectious diseases. These results may help direct future research on MIF-173 G/C in diseases in which the relation is clearer and thus assist the search for more plausible applications.
Collapse
Affiliation(s)
- Oscar Illescas
- Unidad de Biomedicina, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla de Baz, Mexico
| | - Juan C. Gomez-Verjan
- División de Investigación Básica, Instituto Nacional de Geriatría, Mexico City, Mexico
| | - Lizbeth García-Velázquez
- Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - Tzipe Govezensky
- Departamento de Biología Molecular, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - Miriam Rodriguez-Sosa
- Unidad de Biomedicina, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla de Baz, Mexico
| |
Collapse
|
6
|
Wu S, Sun J, Lian J, Shang H, Tao H, Xie J, Lin W. Macrophage migration inhibitory factor promoter polymorphisms (−794CATT5-7) as potential biomarker for early-stage cervical cancer. J Obstet Gynaecol Res 2017; 43:571-579. [PMID: 28160516 DOI: 10.1111/jog.13233] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2016] [Revised: 09/28/2016] [Accepted: 10/07/2016] [Indexed: 11/28/2022]
Affiliation(s)
- Suhui Wu
- Department of Obstetrics and Gynecology, Shanxi Academy of Medical Sciences & Shanxi Dayi Hospital; Dayi Hospital of Shanxi Medical University; Taiyuan China
| | - Jingfen Sun
- Department of Obstetrics and Gynecology, Shanxi Academy of Medical Sciences & Shanxi Dayi Hospital; Dayi Hospital of Shanxi Medical University; Taiyuan China
| | - Junfang Lian
- Department of Obstetrics and Gynecology, Shanxi Academy of Medical Sciences & Shanxi Dayi Hospital; Dayi Hospital of Shanxi Medical University; Taiyuan China
| | - Haixia Shang
- Department of Obstetrics and Gynecology, Shanxi Academy of Medical Sciences & Shanxi Dayi Hospital; Dayi Hospital of Shanxi Medical University; Taiyuan China
| | - Huijuan Tao
- Department of Obstetrics and Gynecology, Shanxi Academy of Medical Sciences & Shanxi Dayi Hospital; Dayi Hospital of Shanxi Medical University; Taiyuan China
| | - Jun Xie
- Department of Biochemistry and Molecular Biology; Shanxi Medical University; Taiyuan China
| | - Weifeng Lin
- Department of Obstetrics and Gynecology, Shanxi Academy of Medical Sciences & Shanxi Dayi Hospital; Dayi Hospital of Shanxi Medical University; Taiyuan China
| |
Collapse
|